Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Randomized Phase III Study Comparing Docetaxel Followed by Cyclophosphamide, Epirubicin and 5-FU to Docetaxel With Capecitabine Followed by Cyclophosphamide, Epirubicin and Capecitabine as Adjuvant Treatment for Early Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00114816
• Other study ID #: FBCG Protocol No. 01-2003
• Secondary ID: Roche protocol n
• Status: Completed
• Phase: Phase 3
• First received: June 17, 2005
• Last updated: May 18, 2007
• Start date: January 2004
• Est. completion date: April 2007

Study information

• Verified date: May 2007
• Source: Finnish Breast Cancer Group
• Contact: n/a
• Is FDA regulated: No
• Health authority: Finland: Finnish Medicines Agency
• Study type: Interventional

Clinical Trial Summary

This study compares two chemotherapy regimens as adjuvant treatment for breast cancer. The study participants are randomly allocated to receive either 3 cycles of docetaxel followed by 3 cycles of CEF (cyclophosphamide, epirubicin and 5-fluorouracil) or to receive 3 cycles of docetaxel plus capecitabine followed by 3 cycles of CEX (cyclophosphamide, epirubicin and capecitabine). The study participants are required to to have a medium to high risk for breast cancer recurrence. The primary aim of the study is to investigate whether addition of capecitabine to a standard taxane/anthracycline regimen will influence recurrence-free survival.

Description:

This is an open-label, two-arm, randomized multi-center phase III trial to compare efficacy and safety of a taxane-anthracycline regimen to a taxane-anthracycline-capecitabine regimen as adjuvant treatment of early breast cancer with an intermediate-to-high risk of cancer recurrence.

Patients diagnosed with early breast cancer with an estimated risk of 25% or greater for distant recurrence within 5 years from the diagnosis will be randomly allocated to one of the following 2 arms (1:1):

• Arm A -- 3 cycles of docetaxel 80 mg/m² intravenous (i.v.) (repeated on day [d.] 22); followed by 3 cycles of CEF (cyclophosphamide 600 mg/m2 i.v., epirubicin 75mg/m² i.v., 5-fluorouracil 600 mg/m2 i.v., repeated on d. 22)

• Arm B -- 3 cycles of TX (docetaxel 60 mg/m² i.v., capecitabine twice daily 900 mg/m² given orally on days 1-15 of the cycle; cycle repeated on d. 22); followed by 3 cycles of CEX (cyclophosphamide 600 mg/m2 i.v., epirubicin 75mg/m² i.v, capecitabine twice daily 900 mg/m² on days 1-15 of the cycle; cycle repeated on d. 22)

Locoregional radiotherapy is given according to the institutional practice after completing adjuvant chemotherapy (Tx3/CEFx3 or TXx3/CEXx3).

All patients with ER and/or PgR positive disease will receive adjuvant endocrine therapy. This will consist of 1 mg p.o. anastrozole (ArimidexR) given for 60 months in women who were post-menopausal prior to chemotherapy (no menstrual periods for > 6 months) or of tamoxifen 20 mg p.o. for 60 months in women who were pre-menopausal prior to chemotherapy.

Use of trastuzumab is allowed in HER-2 positive disease.

Patients will be followed up for 5 years post-randomization.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1500
• Est. completion date: April 2007
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

To be eligible for inclusion in the study, each patient must fulfill each of the criteria below.

• Have provided written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.

• Be female and 18 years of age or older.

• Have histologically confirmed invasive breast cancer.

• High risk of breast cancer recurrence (> 25% within the first 5 years without adjuvant therapy, > 35% within the first 10 years) with one of the following:

• Regional node positive disease (pN+; tumor cells or tumor cell clusters < 0.2 mm in diameter are not counted as metastases);

• Pathological N0 and PgR- and tumor size > 20 mm.

Exclusion Criteria:

Patients who fulfill any of the following criteria will be excluded:

• > 65 years of age.

• ”Special type” histology (mucinous, papillary, medullary, or tubular breast cancer), when pN0.

• ER, PgR and HER-2 status (via in situ hybridization or immunohistochemistry) not determined.

• Presence of distant metastases.

• Previous chemotherapy in the neoadjuvant setting.

• Non-ambulatory or WHO performance status > 1.

• Pregnant or lactating women. Women of childbearing potential (menstruating within 6 months of study entry or with no hysterectomy and age < 55) with either a positive or no pregnancy test at baseline.

• Women of childbearing potential unless using a reliable and appropriate contraceptive method. (Post-menopausal women must have been amenorrheic for at least 6 months to be considered of non-childbearing potential).

• More than 12 weeks between breast surgery and date of randomization.

• Organ allografts with immunosuppressive therapy required.

• Major surgery (except breast surgery) within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery.

• Participation in any investigational drug study within 4 weeks preceding treatment start.

• Patients with a history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.

• History of another malignancy within the last five years except cured basal cell carcinoma of skin or carcinoma in situ of the uterine cervix.

• Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia not well controlled with medication) or myocardial infarction within the last 12 months.

• Abnormal laboratory values:

• Hemoglobin < 10.0 g/dL, neutrophils < 1.5 x 10^9/L, platelet count < 120 x 10^9/L;

• Serum creatinine > 1.5 x Upper Limit of Normal (ULN);

• Creatinine clearance (calculated per Cockroft and Gault) < 50 mL/min;

• Serum bilirubin > ULN;

• ALAT > 1.5 x ULN;

• Alkaline phosphatase > 2.5 x ULN.

• Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease.

• Lack of physical integrity of the upper gastrointestinal tract or those who have clinically significant malabsorption syndrome.

• Inability to swallow tablets.

• Life expectancy of less than 3 months.

• Unwilling or unable to comply with the protocol for the duration of the study.

• Requirement for concurrent use of the antiviral agent sorivudine or chemically related analogues, such as brivudine.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• capecitabine

• docetaxel

Locations

Country	Name	City	State
Finland	Department of Oncology, Helsinki University Central Hospital, Finland	Helsinki

Sponsors (4)

Lead Sponsor	Collaborator
Finnish Breast Cancer Group	AstraZeneca, Hoffmann-La Roche, Sanofi

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrence-free survival
Secondary	Adverse event rate (CTCAE v. 3.0)
Secondary	Overall survival